Skip to content
News
Update on Nasodine Phase 3 trial

Update on Nasodine Phase 3 trial


Firebrick Pharma is pleased to provide an update on our Phase 3 clinical trial of Nasodine® Nasal Spray in the treatment of the common cold. As at 31 October, the trial has so far successfully recruited 224 subjects with early-stage colds into the ITT (‘Intent-To-Treat’ population), with an estimated 100 qualifying for the primary endpoint…

Nasodine patent granted in Singapore

Nasodine patent granted in Singapore


We are pleased to announce that our patent covering Nasodine ® Nasal Spray1 as a treatment and preventative for the common cold has been granted in Singapore. This brings the number of countries where Firebrick’s core patent has been granted to 27, including: The patent is still pending in Canada and Japan. The pending application…

Firebrick to file appeal seeking immediate approval of Nasodine

Firebrick to file appeal seeking immediate approval of Nasodine


Firebrick Pharma announced today that the Company had decided to file an appeal against TGA’s initial decision not to approve Nasodine® Nasal Spray (“Nasodine”) for sale in Australia, based on the existing clinical data. If successful, the appeal could lead to approval of Nasodine sometime in 2022. If unsuccessful, we will re-submit to TGA at…